Skip to main content

Talk Bio

Search This Blog

Moderna adds commercial chief, expands Stephen Hoge's role

on June 18, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Moderna appoints Ester Banque as Chief Commercial Officer effective June 15, 2026, to lead its global commercial organization and support upcoming product launches and market expansion.

President Stephen Hoge expands his role to oversee operational and cross-functional leadership across Research & Development, Manufacturing, and Commercial for Moderna's three franchises, signaling a broader executive mandate.

Reunion Neuroscience announces leadership changes effective June 15, 2026, with Greg Mayes stepping down as President and CEO, succeeded by Sahil V. Kirpekar, M.D., who takes on both roles and joins the Board of Directors.

Sources:

Leadership Team - Moderna

Moderna's Post - LinkedIn

Moderna Announces Organizational Changes to Prepare for Multiple

We are excited to announce expanded roles of two current members of our… | Moderna | 58 comments

Moderna announces executive changes ahead of potential launches

Moderna adds commercial chief ahead of product launches (MRNA)

Moderna expands Hoge's role, names Banque commercial chief

Moderna Overhauls Leadership Ahead of Product Launches

Meet the Moderna Team

Moderna CEO Reshuffles Roles

Moderna, Inc. Announces Appointment of Ester Banque as Chief Commercial Officer, Effective June 15, 2026

Moderna Strengthens Commercial Strategy As Pipeline Advances

Reunion Neuroscience | Reunion Neuroscience

Reunion Neuroscience, Inc. Announces Board and Executive Changes, Effective June 15, 2026

Greg Mayes | LinkedIn

Reunion Neuroscience, Inc. Announces CEO Changes ...

Reunion Neuroscience appoints Sahil V. Kirpekar, M.D., as ...

Reunion Neuroscience Names Greg Mayes As President And CEO

07 Oct Reunion Neuroscience Inc. Announces Executive Changes

Reunion Neuroscience, Inc. kondigt CEO-wissel aan per 15 ...

Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO

Reunion Neuroscience Appoints Mark Pollack, M.D., as Chief Medical Officer

Reunion Neuroscience - The Org

Reunion Neuroscience Inc. (REUN) Leadership & Management Team Analysis - Simply Wall St

Reunion Neuroscience names new CEO | Drug Discovery

Reunion Neuroscience kondigt wijzigingen aan in de raad ...

How this psychedelic drug company went private and raised a $103M Series A

CEO Chief Chief Commercial Officer departure - ActRelationshipType Ester Banque Leadership Moderna Neuroscience discipline Reunion Sahil V. Kirpekar Stephen Hoge

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Pfizer's Monthly GLP-1 Data from VESPER-3: Competitive Weight Loss Validates $10B Metsera Acquisition

Pfizer's Phase 2b VESPER-3 trial of ultra-long-acting GLP-1 RA PF-08653944 (MET-097i) achieved up to 12.3% placebo-adjusted weight loss at 28 weeks with monthly maintenance dosing after initial weekly titration 1 3 4 . Weight loss continued robustly post-switch to monthly dosing with no plateau observed at week 28, supporting Phase 3 advancement including higher 9.6 mg dose 1 3 . Data described as competitive with rivals (9-13% at week 28), validating Pfizer's $10B Metsera acquisition, with 10 Phase 3 trials planned for 2026 1 3 2 . Tolerability profile favorable with mostly mild/moderate GI events; full VESPER-3 data to be presented June 2026 1 3 . Analysts view results as encouraging but note questions on placebo benefits, discontinuations, and comparison to prior weekly data 3 5 . Sources: 1. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust 2. https://www.pharmaceutical-technology.com/anal...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC